SCHEMBL17874149

SCHEMBL17874149

CC(C)(C)[Si](C)(C)Oc1ccc2cc(B(O)O)oc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 7/20 0.59
CA9 Q16790 7/20 0.59
CA1 P00915 6/20 0.59
KDM4E B2RXH2 4/20 0.45
TDP1 Q9NUW8 2/20 0.45
HSD17B10 Q99714 2/20 0.45
MGLL Q99685 1/20 0.45
GAA P10253 3/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 3/20 0.36
MAOB P27338 2/20 0.36
CA2 P00918 3/20 0.35
HSD11B1 P28845 1/20 0.34
SLC16A3 O15427 1/20 0.33
GLA P06280 2/20 0.33
PREP P48147 2/20 0.33
SRD5A1 P18405 1/20 0.33
POLB P06746 1/20 0.33
CA3 P07451 1/20 0.33
AKR1B1 P15121 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19783085 0.89 CA12 (0.58) CA12CA9CA1KDM4ETDP1
SCHEMBL14018173 0.79 CA12 (0.70) CA12CA9CA1KDM4EHSD17B10
SCHEMBL4494679 0.79 KDM4E (0.53) CA12CA9CA1KDM4ETDP1
SCHEMBL29954502 0.76 CA1 (0.52) CA12CA9CA1CA2PREP
SCHEMBL932807 0.76 CA1 (0.52) CA12CA9CA1CA2PREP
SCHEMBL15733448 0.75 CA12 (1.00) CA12CA9CA1KDM4ETDP1
SCHEMBL15733343 0.75 CA12 (1.00) CA12CA9CA1KDM4ETDP1
SCHEMBL7127684 0.74 CA12 (0.57) CA12CA9CA1PREPNPC1
SCHEMBL29952094 0.73 CA12 (0.45) CA12CA9CA1KDM4EHSD17B10
SCHEMBL1621740 0.73 CA12 (0.45) CA12CA9CA1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180022750-A1 6-HYDROXYBENZOFURANYL- AND 6-ALKOXYBENZOFURANYL-SUBSTITUTED IMIDAZOPYRIDAZINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-01-25 US disclosed
US-20180022750-A1 6-HYDROXYBENZOFURANYL- AND 6-ALKOXYBENZOFURANYL-SUBSTITUTED IMIDAZOPYRIDAZINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-01-25 US disclosed
US-20180022750-A1 6-HYDROXYBENZOFURANYL- AND 6-ALKOXYBENZOFURANYL-SUBSTITUTED IMIDAZOPYRIDAZINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-01-25 US disclosed
EP-3237417-A1 6-HYDROXYBENZOFURANYL- AND 6-ALKOXYBENZOFURANYL-SUBSTITUTED IMIDAZOPYRIDAZINES Bayer Pharma Aktiengesellschaft (DE) 2017-11-01 EP disclosed
WO-2016102427-A1 6-HYDROXYBENZOFURANYL- AND 6-ALKOXYBENZOFURANYL-SUBSTITUTED IMIDAZOPYRIDAZINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180022750-A1 6-HYDROXYBENZOFURANYL- AND 6-ALKOXYBENZOFURANYL-SUBSTITUTED IMIDAZOPYRIDAZINES VEGFA, KDR, FLT4 CA12 2628/4885CA9 1853/4885CA1 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.